HOME >> BIOLOGY >> NEWS
Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
14-Sep-2006


Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2017)... the thousands of attendees at this year,s International Consumer Electronics Show (CES), ... measurement devices and services, will be featuring its new line of ULTRA ... special CES Exhibit Suite , the new upper arm and wrist ... WellnessConnected product platform.  Continue Reading ... ...
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
Breaking Biology News(10 mins):
(Date:1/14/2017)... , Jan. 13, 2017  The Alliance for ... in response to FDA final guidance on ... its continued leadership in emphasizing the importance of distinct ... keenly aware of the benefits biosimilars will bring to ... Yet the portion of the Guidance dealing ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci has been ... found among its diverse customer base. The latest entry in this field is ... including BTX and Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, ...
(Date:1/12/2017)... (PRWEB) , ... January 12, ... ... USING VTI’S INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces ... the InterFuse® laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) ...
Breaking Biology Technology:
Cached News: